BioCentury on BioBusiness,
Table: EPS watch
Back to the parent article
Monday, March 3, 2014
At least 20 companies reported earnings last week. Questcor
Pharmaceuticals Inc. (NASDAQ:QCOR) fell 21%, losing nearly $1 billion in
market value, after posting 4Q13 revenues that missed the Street's estimate. In
addition, Citron Research said the company's autoimmune drug H.P. Acthar Gel
repository corticotropin injection faces "severe risk of being pulled off
the market by FDA." Citron cites analysis by a contract laboratory that
found the product contained little or none of the active pharmaceutical
Medivation Inc. (NASDAQ: MDVN) fell 16%, losing
$1 billion in market value, after providing 2014 U.S. net sales guidance for
Xtandi enzalutamide of $500-$535M, below the analyst consensus estimate (see
"Analyst Picks," A20). The cancer drug is partnered with Astellas
Pharma Inc. (Tokyo:4503).
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]